Buntanetap - Phase 3 Trial Fully Enrolled
July 7, 2026
Annovis Bio announced today its Phase 3 trial of oral buntanetap for early Alzheimer’s disease (AD) is fully enrolled. There are 850 pTau217-positive patients across 83 United States sites.
Annovis Bio announced today its Phase 3 trial of oral buntanetap for early Alzheimer’s disease (AD) is fully enrolled. There are 850 pTau217-positive patients across 83 United States sites.
